EXO SUN After-Sun Treatment

Route: Topical application to sun-exposed skin areas.

Apply liberally to all sun-exposed skin (face, neck, chest, arms, legs as needed) as soon as possible after sun exposure. Cool or gently cleanse the skin first if it is particularly hot or sandy. Massage in gently; avoid vigorous rubbing on any sunburned skin. Reapply as needed for comfort and ongoing support. Avoid contact with eyes. This is an after-sun treatment, not a sunscreen; it does not provide UV protection and should not replace sunscreen prior to sun exposure.

Application protocol is prescriber-directed. Typical practice:

• Apply once or twice to affected areas immediately after and in the hours following significant sun exposure.
• For patients with ongoing daily sun exposure (e.g., outdoor workers), prescriber may recommend evening application as part of a daily routine.
• This preparation may also be used after UV-based dermatological procedures (e.g., phototherapy, PDT) per clinician direction.

UV radiation triggers a well-characterized inflammatory and oxidative cascade in skin cells: direct DNA damage (CPD formation), generation of reactive oxygen species (ROS), activation of NF-κB and AP-1 transcription factors, release of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), upregulation of matrix metalloproteinases (MMP-1, MMP-3) that degrade collagen, and generation of the sunburn inflammatory response. EXO SUN targets this cascade:

• Anti-inflammatory miRNA cargo: Exosome-delivered miRNAs suppress NF-κB p65 and p38 MAPK activation, reducing transcription of IL-6, TNF-α, and IL-1β in UV-stressed keratinocytes and fibroblasts.
• Antioxidant proteins: Vesicle-encapsulated antioxidant enzymes (SOD-equivalents, glutathione-related cargo) and anti-lipid peroxidation factors quench ROS generated by UV, protecting cell membranes and DNA.
• Barrier repair growth factors: EGF and TGF-β within vesicles accelerate keratinocyte migration and proliferation needed to restore the barrier disrupted by UV-induced sunburn inflammation and epidermal cell damage.
• MMP suppression: miRNA cargo down-regulates MMP-1 and MMP-3 expression, reducing UV-induced collagenase activity that drives photoaging ECM degradation.

Clinical Context: EXO SUN is indicated for prescriber-directed post-UV exposure management in patients undergoing active photoprotection protocols, those with significant cumulative sun damage (Fitzpatrick phototype I–IV with marked photoaging), or patients who have received UV-based therapeutic procedures. By interrupting the post-UV inflammatory cascade early, the preparation aims to attenuate the cumulative photoaging process. It is complementary to, not a substitute for, pre-exposure broad-spectrum photoprotection.

Monitoring Considerations:

• Monitor overall photoaging progression over time using standardized photography.
• Ensure patient understanding that this preparation does not replace sunscreen.
• Assess tolerability in the first application session; UV-stressed skin may have temporarily increased permeability and sensitivity.

Contraindications:

• Known hypersensitivity to any ingredient in the preparation.
• Do not apply to open blisters from severe sunburn (second-degree burn equivalent) — seek medical attention for severe sun burns before applying any topical preparation.

Warnings & Precautions:

• For topical external use only. Avoid ocular contact.
• This is not a sunscreen and provides no SPF protection. Do not use in place of sunscreen prior to UV exposure.
• UV-stressed skin has temporarily increased permeability — apply with gentle pressure; avoid mechanical trauma.

Drug Interactions:

• No established clinically significant drug interactions for topical after-sun preparations.

Common Side Effects: Generally well tolerated, including on UV-stressed skin. Mild transient cooling sensation or tingling. Rare allergic contact dermatitis.

Store at controlled room temperature (20–25°C / 68–77°F) or as specified on the label for the exosome component. Protect from excessive heat (a concern for a product kept near outdoor/beach use) and direct sunlight. Keep out of reach of children. Use before the BUD assigned by Genesis Compounding.

Is this a sunscreen?

No — EXO SUN is an after-sun treatment designed to help manage the skin's response to UV exposure after it has occurred. It does not provide UV protection and cannot replace a broad-spectrum sunscreen applied before sun exposure.

How quickly should I apply this after sun exposure?

The earlier after UV exposure the better — applying while the inflammatory cascade is in its initiation phase (within the first hours after exposure) provides the best opportunity to interrupt UV-induced inflammatory and oxidative signaling. Cooling the skin with a gentle rinse first can help reduce skin temperature before applying.

Can this be used after UV phototherapy treatments?

Yes — anti-inflammatory exosome preparations may be used post-UV therapeutic procedure to manage post-procedure erythema and support barrier recovery. Coordinate timing and application instructions with your treating clinician.

Is this FDA-approved?

No. This is a prescription-only 503A compounded preparation made by Genesis Compounding per your prescriber's specifications. It is not an FDA-approved drug product.

Can I use this on my children after a day in the sun?

This is a prescription preparation intended for use only in the specific patient for whom it was prescribed. Pediatric safety data for exosome preparations are limited; discuss with the prescribing clinician before applying to children.